title: Japanese guidelines for the management of pemphigus.
abstract: The Committee for Guidelines for the Management of Pemphigus was organized as one element of the Japanese Dermatological Association (JDA) and the Ministry of Health, Labour, and Welfare (MHLW) Research Project on Measures for Research Committee for Intractable Skin Disease. Pemphigus has been defined as a group of intractable autoimmune blistering diseases caused by anti-desmoglein 1 and/or anti-desmoglein 3 IgG autoantibodies by the MHLW. The diagnosis of this condition and the criteria for assessing its severity are based on suggestions from the MHLW Research Group. The clinical practice guidelines presented here are those that are currently recommended in Japan. However, symptoms and complications can vary widely among individual pemphigus patients, so not all therapies will be required to be in complete agreement with these guidelines.
authors.forename: Masayuki
authors.initials: M
authors.lastname: Amagai
authors.forename: Akiko
authors.initials: A
authors.lastname: Tanikawa
authors.forename: Tomoko
authors.initials: T
authors.lastname: Shimizu
authors.forename: Takashi
authors.initials: T
authors.lastname: Hashimoto
authors.forename: Shigaku
authors.initials: S
authors.lastname: Ikeda
authors.forename: Michiko
authors.initials: M
authors.lastname: Kurosawa
authors.forename: Hironori
authors.initials: H
authors.lastname: Niizeki
authors.forename: Yumi
authors.initials: Y
authors.lastname: Aoyama
authors.forename: Keiji
authors.initials: K
authors.lastname: Iwatsuki
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Kitajima
mesh_terms: D019317:Evidence-Based Medicine; D006801:Humans; D007564:Japan / Q000453:epidemiology; D010392:Pemphigus / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology / Q000473:pathology; D012720:Severity of Illness Index; D012867:Skin / Q000473:pathology
keywords: autoantibody; desmoglein; diagnosis; therapy